ArticleAllergy2026
Metabolite-Based Endotypes of Asthma Reveal Distinct Clinical Characteristics and Immune Cell Signatures.
Article in Allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAsthma control is commonly defined by symptom burden and recent exacerbation history. However, symptom-based clinical stability does not necessarily reflect biological quiescence, and heterogeneity in lung function and airway structure may persist despite apparent clinical control. This study aimed to determine whether blood-based metabolomic profiling can discriminate biologically distinct subgroups within a clinically stable asthma population.
methodsWe conducted a prospective observational study of adults with clinically stable asthma, defined by sustained symptom control and absence of recent exacerbations under maintenance inhaled corticosteroid-based therapy. Untargeted plasma metabolomic profiling was performed using liquid chromatography-tandem mass spectrometry, and metabolite-derived subgroups were identified by consensus clustering. Lung function, airway structure, small-airway physiology, and peripheral immune cell profiles were compared across clusters, with associations assessed using regression analyses.
resultsThree metabolite-derived subgroups were identified based on patterns in the relative abundance of selected representative metabolites. Symptom control and exacerbation history were comparable across clusters, whereas lung function, airway wall thickness, small-airway physiology, and immune cell profiles differed substantially. Cluster 1 (C1; Remodeling-prone), characterized by greater relative abundance of glycerophospholipid-related metabolites, showed lower post-bronchodilator FEV
conclusionsMetabolomic profiling reveals biologically distinct subgroups among clinically stable asthma, indicating that symptom-based stability does not necessarily reflect biological homogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.